EU/3/18/2111

About

On 14 December 2018, orphan designation (EU/3/18/2111) was granted by the European Commission to RHEACELL GmbH & Co. KG, Germany, for allogeneic ABCB5-positive limbal stem cells (also known as LSC2) for the treatment of limbal stem cell deficiency.

Key facts

Active substance
Allogeneic ABCB5-positive limbal stem cells
Disease / condition
Treatment of limbal stem cell deficiency
Date of first decision
14/12/2018
Outcome
Positive
EU designation number
EU/3/18/2111

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

RHEACELL GmbH & Co. KG
Im Neuenheimer Feld 517
69120 Heidelberg
Germany
Tel. +49 6221 718330
E-mail: office@rheacell.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating